探讨布洛芬缓释胶囊联合体外冲击波对膝关节骨关节炎的治疗效应。

2018年9月至2019年9月，从重庆市人民医院纳入膝关节骨关节炎患者作为前瞻性随机对照临床研究。纳入标准：初治单侧膝关节骨关节炎；依从性良好者。排除标准：既往有其他膝关节疾患；膝关节强(僵)直；Kellgren-Lawrence分级为Ⅳ级的患者；对非甾体类抗炎药(NSAIDs)类药物禁忌或过敏的患者；合并其他内科系统疾病等。共198例患者通过随机数字表法分别分入联合组、布洛芬组、冲击波组。联合组给予布洛芬缓释胶囊联合体外冲击波治疗；布洛芬组给予单纯布洛芬缓释胶囊治疗；冲击波组给予单纯体外冲击波治疗，疗程5周。于治疗开始后8周时采用膝关节损伤和骨关节炎评分(KOOS)、加拿大西安大略和麦克玛斯特大学骨关节炎指数(WOMAC)及SF-12生活质量评分对三组患者进行评价，并记录三组患者并发症发生率。结果用单因素方差分析、LSD-t检验、配对t检验和卡方检验进行分析。

布洛芬缓释胶囊联合体外冲击波治疗可显著改善骨关节炎患者膝关节KOOS、WOMAC及SF-12生活质量评分。联合组患者的疼痛(F＝174.5，P<0.001)、症状(F＝12.991，P<0.001)及功能评分(F＝6.009，P＝0.003)等显著改善，效应较单纯给予布洛芬缓释胶囊或体外冲击波治疗更佳。同时，并不明显增加治疗相关并发症的发生率(χ²＝2.479，P>0.05)。

布洛芬缓释胶囊联合体外冲击波对骨关节炎具有良好的治疗效应，效果优于单用布洛芬缓释胶囊或冲击波治疗。

To evaluate the clinical results of combination of the ibuprofen sustained release capsules and extracorporeal shockwave therapy of knee osteoarthritis.

From September 2018 to September 2019 in Chongqing General Hospital, the patients with knee osteoarthritis were enrolled in this prospective, randomized and comparative clinical study. Inclusion criteria: initial treatment of unilateral knee osteoarthritis, good compliance. Exclusion criteria: previous knee disorders; arthroclisis (stiff) of knee; Kellgren-lawrence grade Ⅳ; the patients who were contraindicated or allergic to non-steroidal anti-inflammatory drug(NSAIDs) or complicated with other systematic diseases. One hundred and ninety-eight patients were randomized divided into the combination group, the ibuprofen group, and the shockwave group by the random number table. The combination group were treated with ibuprofen sustained release capsules and extracorporeal shockwave therapy; the ibuprofen group were treated with ibuprofen sustained release capsulesalone; the shockwave group were treated with extracorporeal shockwave therapy alone. The clinical results were evaluate by the knee injury and osteoarthritis outcome score (KOOS), Western Ontario and McMaster Universities osteoarthrtis index(WOMAC) and the 12-item short-form health survey (SF-12) at eight weeks following the treatment. The complications related to the treatment were also recorded. The results were analyzed by one-way analysis of variance, LSD-t test, paired-samples t test and chi square test.

Ibuprofen sustained release capsules and extracorporeal shockwave therapy could significantly improve the KOOS, WOMAC and SF-12 quality of life scores. The pain (F=174.5, P<0.001), symptoms (F=12.991, P<0.001) and function scores (F=6.009, P=0.003) were significantly improved in the combination group, which were better than that of ibuprofen sustained release capsules or extracorporeal shockwave therapy only. The complications related to the treatment were not increased (χ²=2.479, P>0.05).

Ibuprofen sustained release capsules combined with extracorp oreal shockwave therapy has a good treatment effect for knee osteoarthritis, which is better than ibuprofen sustained release capsules or extracorporeal shockwave therapy alone.